Unlocking healthcare potential for patients
Leveraging our expertise to address unmet medical needs
our products
Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals.
Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies.
Phase 2B*
BPS-804
Osteogenesis Imperfecta (OI) *POTENTIALLY PIVOTALPhase 2B
BGS-649
Hypogonadotropic Hypogonadism (HH)Phase 2
ACUMAPIMOD - BCT-197
Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)partner with us
Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines.
Interested in a potential collaboration?Investors
Share Price
Events and conferences
- 19 May 2017 Mereo BioPharma presented at at the American Thoracic Society meeting in Washington, 19-24 May 2017
- 24 Jan 2017 Mereo BioPharma presented at at the Shares Spotlight Evening in London
- 10 Jan 2017 Mereo BioPharma Group plc presented at the 9th Annual Biotech Showcase, 11:00am PST (San Francisco, USA)